Richard A. Meier
Known title: DirectorCIK: 0001227305
Associated companies
Transaction History
| BMRN | ▲ Buy | Grant | 6,650 | $0 | 5/20/2025 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 6,600 | $416K | 6/3/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 5,451 | $417K | 6/3/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 7,080 | $0 | 5/21/2024 | View on chart |
| BMRN | ▼ Sell | Gift | 3,000 | $0 | 1/8/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 4,190 | $0 | 5/23/2023 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 8,500 | $576K | 5/12/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 6,137 | $576K | 5/12/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 4,980 | $0 | 5/24/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 8,500 | $318K | 5/2/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 3,860 | $317K | 5/2/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 18 | $1K | 5/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.